Keyword: Ipsen Pharmaceuticals
Ivana Magovčević-Liebisch, Chief Business Officer, Ipsen
NICE has been weeding out some meds from the Cancer Drugs Fund (CDF), and thyroid cancer drugs from Sanofi and Ipsen are about to be plucked.
Big Pharma figures the Amgen vs. Sanofi patent decision, when it comes, could upturn their pipeline drugs and development choices, so they're weighing in.
France’s Ipsen will get a manufacturing foothold in the U.S. with a new deal to expand its oncology reach in the country.
France's Ipsen has struck a deal to buy the underperforming pancreatic cancer drug of U.S.-based Merrimack Pharmaceuticals in a deal that could top $1 billion.
France’s Ipsen has pledged it will get nearly a third of its revenue out of the U.S. by 2020 and has named American and pharma vet David Meek its new CEO to see that that happens. Meek recently lost his job as the former head of oncology at Baxalta when Shire last month closed its buyout of the Baxter spinoff.
F. Michael Ball, the former Hospira CEO who last month took over the top spot at Novartis' ($NVS) troubled Alcon unit, already had plenty on his to-do list. The division's sales are way off,...